Global Epilepsy Treatment Market, By Condition (Epilepsy Drug Resistant/Intractable Epilepsy, Others), Drug (First-Generation, Second-Generation, Third-Generation), Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies), End Users (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Centers) – Industry Trends and Forecast to 2029.
Epilepsy Treatment Market Analysis and Size
According to the World Health Organization reported that in 2017, the total cost of healthcare per person worldwide was USD 1,064.741. The cost of healthcare per person worldwide increased from USD 864.313 in 2008 to USD 1,110.841 in 2018, with the United States as the top payer at USD 10, 623.85 per capita in 2018. Domestic general government healthcare spending in the United States increased from USD 3515.82 in 2008 to USD 5355.79 in 2018. These are a few of the elements that have contributed to market expansion in recent years.
Data Bridge Market Research analyses that the epilepsy treatment market which was USD 1330.53 million in 2021, would rocket up to USD 2152.88 million by 2029, and is expected to undergo a CAGR of 6.20% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Epilepsy Treatment Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Million, Volumes in Units, Pricing in USD
Condition (Epilepsy Drug Resistant/Intractable Epilepsy, Others), Drug (First-Generation, Second-Generation, Third-Generation), Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies), End Users (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Centers)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Pfizer Inc. (U.S.), Novartis AG (Germany), Abbott (U.S.), Neurelis Inc. (U.S.), GSK plc (U.K.), Johnson & Johnson Services Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (U.S.), Sumitomo Dainippon Pharma Co. Ltd (Japan), Bausch Health Companies Inc. (Canada), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), UCB S.A. (China), Marinus Pharmaceuticals Inc. (U.S.), Eisai Co. Ltd (Japan), H. Lundbeck A/S (Denmark), Supernus Pharmaceuticals Inc (U.S.), DAIICHI SANKYO COMPANY LIMITED (Japan)
The term "epilepsy" describes a long-term neurological condition that results in frequent, unjustified seizures. A person with epilepsy frequently experiences seizures that have no known cause. The actual origins of these seizures are yet unknown, but they may be brought by some stressful event or a prior brain injury. The disorder often affects both adults and children, however the danger of infection is higher in the elderly population.
Epilepsy Treatment Market Dynamics
- Rise in injuries
The key drivers driving the epilepsy treatment market are the rise in accidents and brain injuries and the high rates of post-traumatic epilepsy (PTE) and post-traumatic seizure (PTS) occurrence in patients with brain injuries. The expansion of the epilepsy treatment market is accelerated by the rise in government funding for improving and developing effective medications and treatments for seizures, as well as the rise in R&D activities to provide cutting-edge healthcare facilities.
- Technological advancements
The market for epilepsy treatments is also impacted by groups working together to provide physicians and the public with better treatment options and awareness training initiatives.
- Rise in the geriatric population
The ageing population, rising epilepsy rates, increased public awareness of treatment alternatives, and declining treatment costs all favor the market. The development of new medications and therapeutic options and the approval and introduction of new products provide lucrative opportunities to the players in the epilepsy treatment market during the forecast period of 2022 to 2029. market for treating epilepsy.
- Increase in the number of research and development activities
The initiatives by the government and advancement in drugs and treatments across the globe are escalating the growth of epilepsy treatment market.
On the other hand, lack of affordability and emergence of epilepsy therapeutic methods in the developing nations are factors expected to obstruct the epilepsy treatment market.
This epilepsy treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the epilepsy treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Epilepsy Treatment Market
The pandemic interfered with neurology activities such as medical training and research. Epileptic treatment facilities as well as epilepsy patients are socially impacted by COVID-19. Due to the possibility of SARS-CoV-2 transmission from patient to patient or from healthcare practitioner to patient, patients' access to healthcare facilities has been severely constrained. Furthermore, standby admissions in hospitals with COVID-19 inpatients or in locations with widespread COVID-19 illness have been severely restricted due to worries about patient-to-patient transmission.
- In August 2021, In an agreement signed between Yuyu Pharma and Novartis Korea, Yuyu obtained the exclusive distribution rights for three prescription drugs, including Tegretol, a medication containing the drug carbamazepine used to treat diseases including epilepsy.
- In February 2021, A leading provider of remote diagnostics and monitoring, BioTelemetry, Inc., was purchased by Koninklijke Philips N.V.
Global Epilepsy Treatment Market Scope
The epilepsy treatment market is segmented on the basis of condition, drug, distribution channel and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Epilepsy Drug Resistant/Intractable Epilepsy
- Retail Pharmacies
- Online Pharmacies
- Ambulatory Surgical Centers
- Diagnostic Centers
Epilepsy Treatment Market Regional Analysis/Insights
The epilepsy treatment market is analysed and market size insights and trends are provided by country, condition, drug, distribution channel and end users as referenced above.
The countries covered in the epilepsy treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the epilepsy treatment market because of the favourable government initiatives with the purpose to enhance the healthcare system.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the rise in government funding and support to improve the treatment facilities especially in the emerging economies.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Epilepsy Treatment Market Share Analysis
The epilepsy treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to epilepsy treatment market.
Some of the major players operating in the epilepsy treatment market are:
- Pfizer Inc. (U.S.)
- Novartis AG (Germany)
- Abbott (U.S.)
- Neurelis Inc. (U.S.)
- GSK plc (U.K.)
- Johnson & Johnson Services Inc. (U.S.)
- Teva Pharmaceutical Industries Ltd. (U.S.)
- Sumitomo Dainippon Pharma Co. Ltd (Japan)
- Bausch Health Companies Inc. (Canada)
- Sanofi (France)
- Takeda Pharmaceutical Company Limited (Japan)
- UCB S.A. (China)
- Marinus Pharmaceuticals Inc. (U.S.)
- Eisai Co. Ltd (Japan)
- H. Lundbeck A/S (Denmark)
- Supernus Pharmaceuticals Inc (U.S.)
- DAIICHI SANKYO COMPANY LIMITED (Japan)